JACC Journals

A 60-year-old woman underwent percutaneous coronary intervention (PCI) for non–ST-segment elevation myocardial infarction, receiving aspirin and prasugrel. After recurrent unstable angina, repeat PCI was performed, and dual antiplatelet therapy was resumed. One month later, she developed diffuse ecchymoses and progressive anemia.

Find out what happened next in :

Acquired Hemophilia A During Prasugrel Therapy After Recurrent Acute Coronary Syndrome: AbstractBackgroundAcquired hemophilia A (AHA), a rare autoimmune bleeding disorder caused by factor VIII inhibitors, may be overlooked in patients receiving antiplatelet therapies.Case SummaryA 60-...

Coronary hematoma is a major postprocedural complication in the current modern PCI era, although the event rate is low. To avoid emergent return to the catheterization laboratory because of recurrent ischemia, it is important to recognize the angiographic and intravascular imaging features.

Get the details in : https://bit.ly/4vkl8TE

High-sensitivity cardiac troponin I (hs-cTnI) levels were not associated with cumulative anthracycline dose and were only weakly associated with left ventricular ejection fraction decline at 6 months. These findings suggest hs-cTnI elevation may not reliably predict cardiac dysfunction after anthracycline chemotherapy.

Get the details in : https://bit.ly/4dYreSJ

Obesity: a driver in , but in ? An amplifier with a paradox. Does treating change disease course in HFrEF? No dedicated HFrEF trial has answered that yet.

Read the review in : https://bit.ly/43GZqxl

🚨 Upcoming mini-focus issue seeks submissions that advance in cardiovascular care, including outcomes research, community partnerships, and implementation strategies to reduce disparities and improve cardiovascular outcomes.

Submit your work today: https://www.jacc.org/call-for-papers/jacc-advances?

Here's a case of a 35-year-old African American woman with recurrent chest pain who was diagnosed with severe multivessel CAD despite minimal traditional cardiovascular risk factors.

Further evaluation revealed markedly high Lp(a) levels. She underwent successful percutaneous coronary intervention and achieved optimal low-density lipoprotein cholesterol (LDL-C) control with high-intensity statin therapy and a PCSK9 inhibitor. Despite aggressive lipid-lowering therapy, she developed recurrent angina within 6 months, and repeat coronary angiography demonstrated disease progression.

Get the details in :

HTTP Status 429 – Too Many Requests

High-resource community DOES NOT equal ≠ low-risk patients. 🚨 Social risk statistics at a population-level may MISS vulnerable individuals at major mortality risk❗ https://bit.ly/4ecd29R

Elevated lipoprotein(a) [Lp(a)] is associated with higher relative risk across coronary artery calcium (CAC) strata, including CAC of 0. Among individuals with CAC of 0, absolute event rates remain low even when Lp(a) is elevated. CAC scoring remains a powerful tool for risk assessment among individuals with elevated Lp(a).

Learn more in : https://bit.ly/4edAl32

In this editorial, the authors discuss real-world use of direct oral anticoagulant antidotes in Japan, highlighting data on andexanet alfa in activated factor X inhibitor–related major bleeding🩸

Findings support comparable safety and effectiveness vs Western data, reinforcing their role. https://bit.ly/4dOjbrD